Because of the cumulative effect of inherited minute alterations of multiple genes, what the cardiovascular system actually does over a lifetime wanders away from what it would have done. In other words, a dreadful process of atherosclerosis that would have devastated the cardiovascular system of an individual does not happen, or maybe one that was not going to happen does. What was seemingly too complex to predict, the genetic contribution to the development of complex traits like atherosclerosis and other common forms of cardiovascular disease, might become affordable. We owe this new opportunity in part to the ability to sequence the human and related genomes. Single nucleotide polymorphisms (SNPs) represent the most frequent and simplest alteration of this sequence. Unprecedented efforts are underway to identify both SNPs and more complex polymorphisms and to establish their relationship to susceptibility for common ailments and to drug response for patients with heart disease.
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Ischemic heart disease and adverse events following revascularization procedures represent a complex interaction of vascular injury, inflammation and thrombosis. Within the past decade, however, our understanding of ischemic heart disease has become even more sophisticated as recent discoveries have revealed the influence of gene variants on the development of atherosclerotic disease and arterial thrombosis. The pioneers of the field have already studied inherited variants affecting genes involved in processes relevant to atherosclerosis, ranging from cholesterol metabolism to arterial thrombosis. Based on this information, scientists and cardiologists have become increasingly aware that ischemic heart disease represents a polygenic disorder. Furthermore, we have realized that the impact of these genes is mediated by the presence of SNPs, in a context of environmental factors that can influence their penetrance vis-à-vis the disease process.
The role of platelets in unstable coronary syndromes and adverse events following coronary intervention are typical examples of the interplay between genetic and environmental factors. First, platelet activation is dependent upon exposure to disrupted endothelium, circulating cytokines and other agonists released during plaque rupture or vascular injury during angioplasty. Second, a number of genetic polymorphisms within the subunits of platelet receptors may also induce gain or loss of function, thereby predisposing some individuals to thrombotic events. Gain or loss of function may be secondary to polymorphisms that either encode a missense mutation (the resulting codon provokes a change in amino acid) or modify the level of expression of the gene product. Although the mechanism of platelet activation and thrombus formation is generally well established, much controversy remains whether individual platelet polymorphisms contribute to an increased likelihood of ischemic events. In this issue of the Journal, Meisel et al. (2) have studied the association of a platelet receptor variant with acute coronary syndromes and adverse events following percutaneous coronary interventions.
PLATELET POLYMORPHISMS IN ISCHEMIC HEART DISEASE
The major platelet membrane glycoproteins (GP) involved in primary hemostasis are: 1) GPIb-IX-V, the von Willebrand factor (vWf) receptor responsible for initial platelet adhesion to the subendothelium; 2) GPIIb-IIIa, the fibrinogen receptor that cross-links adjacent platelets and is required for platelet aggregation; and 3) GPIa-IIa, the collagen receptor that stabilizes platelet adhesion. The GPIb polymorphisms. In the event of endothelial injury and exposure to the vWf-rich subendothelial matrix, the GPIb-IX-V complex is responsible for securing platelets to the vessel wall under conditions of high shear stress (Fig.  1) . Specifically, the alpha chain of GPIb, GPIb␣, is capable of binding both vWf and thrombin. Glycoprotein Ib␣ contains two known polymorphisms that affect the structure, and a third polymorphism that may alter gene expression of this subunit of the vWf receptor. The first (Ko polymorphism) involves a single cytosine (C) to thymidine (T) substitution in the GPIb␣ gene at nucleotide 434, resulting in the amino acid methionine at position 145 in place of threonine. The second polymorphism is due to a variable number of tandem repeats (VNTR) in a 39 base pair sequence that codes for a 13 amino acid fragment within GPIb␣. This fragment can be present as a single copy or repeated up to four times. By increasing the length of GPIb␣, VNTR is hypothesized to facilitate platelet interaction with the subendothelial matrix and predispose affected individuals to increased thrombotic risk (3). Finally, a T to C single nucleotide substitution at position Ϫ5 from the ATG start codon characterizes the Kozak sequence polymorphism. Although it does not alter structure, the Kozak polymorphism may increase surface expression of GPIb␣ (2, 4) . In one study, GPIb-IX-V receptor density on the platelet surface correlated with genotype; TT homozygous platelets expressed the least GPIb␣, whereas CC homozygous platelets expressed the most (4). Importantly, these findings have not been verified in subsequent research (5) .
Adding to the controversy over platelet polymorphisms are studies associating GPIb␣ variants with an increased risk of ischemic events (6 -8) . The interpretation of these studies is further blurred by variations in study design, patient demographics and clinical presentation. In this issue of the Journal, Meisel et al. (2) add to our understanding of the GPIb␣ receptor as a potential risk factor for coronary artery disease and adverse events complicating catheterbased interventions. In this case-controlled study, the investigators genotyped nearly 1,000 patients with coronary artery disease and compared the frequency of the Kozak polymorphism to matched controls. In a second part, they examined the role of the Ϫ5C allele as a predictor of short-term complications following percutaneous coronary interventions. Compared to the wild-type allele (Ϫ5T/T), carriers of the Ϫ5C allele were more likely to present with an unstable coronary syndrome and/or experience a periprocedural adverse event following balloon angioplasty.
Unlike previous studies examining the role of the Ϫ5C allele in ischemic heart disease, the study by Meisel et al. (2) is the first to associate the GPIb␣ polymorphism with an increased risk of developing an unstable coronary syndrome or ischemic complication following percutaneous coronary intervention. Among nearly 2,500 patients undergoing angioplasty, Santoso et al. (9) found no relationship between the Kozak polymorphism and ischemic events, except for possibly a greater severity of coronary artery disease in younger patients who were homozygous with the Ϫ5C allele. Still other smaller studies have failed to confirm the association between the Kozak sequence polymorphism and ischemic events (10, 11) .
Exactly why carriers of the Ϫ5C allele experience a higher rate of adverse events following balloon angioplasty, but not after atherectomy or stenting, is puzzling. As the investigators hypothesized, it seems intuitive that any mutation promoting platelet adhesion would increase the risk of complications following a procedure that intentionally disrupts the endothelium. However, the increased risk associated with the Kozak polymorphism is found only with balloon angioplasty and not with other interventions known to injure the endothelium or involve angioplasty (e.g., predilation with balloon angioplasty prior to stenting). Moreover, established predictors of adverse events following catheter-based interventions (e.g., diabetes, lesion morphology, among others) vary considerably among the groups in the present study, and the use of GPIIb-IIIa inhibitors (known to reduce periprocedural ischemic complications) was not specified. Although we do not have a molecular mechanism to explain the discrepancy between various angioplasty procedures relative to the Kozak polymorphism, the data, if confirmed, could be useful in the selection of the appropriate procedure for individual patients. Pl A2 polymorphism of GPIIIa. Glycoprotein IIIa, together with GPIIb, constitutes the fibrinogen receptor (GPIIb-IIIa, or integrin ␣ 2 ␤ 3 ), whose engagement represents the final common pathway for platelet aggregation (Fig. 2) . Due to the substitution of a cytosine for a thymidine at position 1565 in exon 2 of the GPIIIa gene, the platelet antigen 2 (Pl A2 ) variant displays a proline instead of a leucine at amino acid 33. The structural change in GPIIb-IIIa that is induced by the Pl A2 variant is the cause for a severe form of neonatal alloimmune thrombocytopenia. Similar to the GPIb␣ polymorphism, Pl A2 has been implicated in arterial thrombosis and the development of unstable coronary syndromes. Specifically, a high prevalence of the Pl A2 allele has been reported in patients with unstable angina or myocardial infarction (MI) and in siblings of patients with a history of premature ischemic heart disease (12,13). Mikkelson et al. (14) also reported a higher prevalence of Pl A2 among victims of sudden cardiac death whose coronary arteries contained thrombus. Still other studies have not confirmed the association between Pl A2 and MI (15), maintaining the controversy over the influence of the Pl A2 polymorphism. Despite the variance in epidemiologic data, most studies examining the molecular effect of the Pl A2 polymorphism on GPIIb-IIIa function have been consistent, showing that the mutation results in increased platelet responsiveness (16, 17) .
Platelet antigen 2 polymorphism has also been related to a higher incidence of adverse ischemic events following catheter-based procedures. As previously described, catheter-based interventions with coronary stenting are a major stimulus for platelet activation. Although the use of intracoronary stents has improved both short-and longterm clinical outcomes by maximizing acute procedural luminal gain and reducing the incidence of restenosis, the disruption of the endothelium and the placement of a metallic stent promote platelet adhesion and thrombus formation. Both platelet adhesion and aggregation also contribute substantially to restenosis by promoting the migration and growth of smooth muscle cells. Walter Although these studies differ in their conclusion relative to the strength of the impact of Pl A2 on adverse events, substantial differences in the design and end points among the studies must be noted. In addition, the antithrombotic regimen varied considerably among these studies. We have previously reported on the gradual beneficial effect of improved antiplatelet regimens on the occurrence of thromboembolic complications in stent patients displaying the Pl A2 polymorphism (21) . Hence, with the use of thienopyridine derivatives and GPIIb-IIIa blockers, outcome differences between Pl A1/A1 homozygous and Pl A1/A2 heterozygous individuals seem to become blurred. However, Pl A2/A2 homozygous patients appear to remain at higher risk despite therapeutic advances (19, 22) . GPIa polymorphisms. The two polymorphisms in the gene for GPIa occur at nucleotides 807 (C or T) and 873 (G or A) and are associated with up to 10-fold variation in receptor density on the platelet surface. Because these polymorphisms do not result in an amino acid substitution, they are considered silent polymorphisms and do not produce alloantigens. A third polymorphism at nucleotide 1642 results in the substitution of glutamic acid for lysine. Despite the possibility that these polymorphisms may result in an increased number of collagen receptors on the platelet surface, studies examining the role of GPIa mutations in acute coronary syndromes have reported conflicting results (23-25). 
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TRANSLATING GENETIC STUDIES INTO CLINICAL PRACTICE
With so many conflicting results from epidemiologic studies of platelet polymorphisms, how should clinicians interpret the findings by Meisel et al. (2)? Should health care providers begin potentially costly screening programs to predict cardiovascular risk or instead dismiss these results as inconclusive evidence? Although it is appealing to attribute much of the disagreement among studies to design or patient populations, it is also important to recognize that the clinical diagnosis of acute coronary syndromes includes a broad range of phenotypic characteristics. Moreover, the relative impact of platelet polymorphism such as GPIb␣ may vary according to multiple factors such as age, gender, smoking history, diabetes or medications. Although platelet polymorphisms are a promising addition to more established cardiovascular risk factors, identifying genetic variants as a single cause of cardiovascular disease would be an oversimplification; instead, the contribution of these polymorphisms should also be considered in the context of nongenetic factors. It appears most appropriate to accept the present study as part of a growing body of evidence to define the role of inherited platelet polymorphisms in cardiovascular disease. To date, no single trial has conclusively established the importance of platelet polymorphisms. Until a large database involving thousands of patients is able to reconcile divergent findings satisfactorily, the controversy will remain. Considering inheritance patterns, the accuracy of genotyping and the impact of environmental factors, the required sample size to have adequate power has been estimated to include several thousands of patients (26) . Therefore, studies should encourage carefully supervised genetic sampling as part of larger clinical trials or even routine patient care to create larger databases.
Aside from describing a relationship between platelet polymorphisms and cardiovascular disease, such studies should also motivate scientists to define the biologic effects of inherited platelet traits more accurately. In the case of GPIb␣, for example, there is uncertain evidence whether the mutation definitely results in a greater number of platelet membrane receptors. Understanding the interaction of platelet polymorphisms with cardiovascular risk factors and endovascular procedures may also influence treatment strategies targeting a specific susceptibility gene implicated in coronary thrombosis. Considering the increased risk of the Pl A2 polymorphism for adverse events in patients undergoing coronary stenting, affected patients might benefit from a more intensive antithrombotic regimen of extended therapy with both aspirin and clopidogrel (21) . Platelets from Pl A2 -positive patients may be more resistant to inhibition with aspirin than those from Pl A1/A1 homozygous patients in the presence of collagen. However, treatment with the combination of aspirin and clopidogrel in Pl A2 -positive patients appears to attenuate collagen-induced platelet aggregation, such that their platelet inhibition is no longer different from that of Pl A1/A1 patients receiving aspirin alone (P. J. Goldschmidt-Clermont, personal communication, 2001). In addition, statin therapy following coronary stenting may abolish the increased incidence of restenosis observed among Pl A2 carriers compared to Pl A1/A1 homozygotes (27) . Despite the substantial research activity in the genetics of coronary artery disease, relatively little coordinated effort has been made to confirm the associated risks of specific gene polymorphisms. As a result, identifying risk associated with genetic discoveries and translating this knowledge into clinical practice will likely occur gradually rather than by one revolutionary discovery. To solve this problem, future studies should consist of larger studies that adhere to the same standards as contemporary large-scale randomized trials for drug development. Including mechanistic studies as part of clinical trials will also facilitate our understanding of the functional significance of these polymorphisms, help define the impact of these mutations on clinical outcomes and validate case-control association studies. A spin-off effect of these studies might be a better definition of phenotypes for the group of syndromes that we have somewhat arbitrarily assembled under the generic name of "acute coronary syndromes." Only through a larger collective effort will the role of platelet polymorphisms and other susceptibility genes for cardiovascular disease be defined. Then, the translation of the human genome project into information that is directly relevant to the betterment of our patients may become a reality. Just as the "butterfly flapping its wings today produces a tiny change in the state of the atmosphere" (1), the impact of slight changes within relevant genes for heart disease will become, once and for all, measurable.
